Skip to main content
Premium Trial:

Request an Annual Quote

10x Genomics Prices Upsized $440M Public Offering

NEW YORK – Single-cell and spatial molecular analysis firm 10x Genomics announced on Friday the pricing of an upsized underwritten public offering of Class A common stock at $110 per share, before underwriting discounts and commissions.

The Pleasanton, California-based firm is now offering 4 million shares, plus an option for the underwriters to purchase an additional 600,000 shares at the public offering price. Initially, the company said it planned to offer 3.5 million shares plus an underwriters' option of 500,000 shares. The firm expects the offering to close on Sept. 15, 2020.

JP Morgan, Bank of America, and Cowen and Company are underwriters for the offering. Stifel and William Blair are acting as co-managers.

The firm went public a year ago, raising $410.8 million in net proceeds.

In Friday morning trade on the Nasdaq, shares of 10x Genomics were up nearly 3 percent at $116.75.

The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.